In a retrospective analysis by Sabari et al. which included 147 patients with MET exon 14-altered NSCLC, the ORR to ICIs was reported at 17%, with a median PFS of 1.9 months [130]. The gene discussed is MET; the disease is non-small cell lung carcinoma.